drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Investigational antibody–drug conjugate (ADC) comprising a tumor-targeting antibody linked to a cytotoxic payload; binds a tumor cell-surface antigen, is internalized, and releases an intracellular toxin to kill antigen-expressing HER2-negative breast cancer cells. Target antigen and payload not specified.
nci_thesaurus_concept_id
C193454
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated, via a cleavable linker, to the exatecan derivative and topoisomerase-1 inhibitor SHR9265, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-TROP-2 ADC SHR-A1921 targets and binds to TROP-2 expressed on tumor cells. Upon binding, internalization and linker cleavage, SHR9265 is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing TROP-2. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-TROP-2 IgG1 antibody-drug conjugate linked via a cleavable linker to the exatecan-derived topoisomerase I inhibitor SHR9265. After binding TROP-2 on tumor cells and internalization, the payload is released to inhibit topoisomerase I, blocking DNA replication and inducing DNA damage–mediated cell cycle arrest and apoptosis in TROP-2–expressing (e.g., HER2-negative) breast cancer cells.
drug_name
SHR-A1921
nct_id_drug_ref
NCT06433609